Lynparza conveyed positive results in BRCA-mutated high-risk early breast cancer


According to brand-new data presented at the 2021 American Society of Clinical Oncology annual meeting, Merck and Co and AstraZeneca’s PARP inhibitor Lynparza conveyed positive results in BRCA-mutated high-risk early breast cancer.

Phase III OlympiA trial data demonstrated that Lynparza decreased the chance of second cancers, invasive breast cancer recurrence or death by forty-two per cent in the overall trial population, including those who had finished standard neoadjuvant and local treatment or adjuvant chemotherapy. Eight-five-point-nine per cent of patients treated with Lynparza remained free of second cancers and invasive breast cancer versus seventy-seven-point-one per cent on placebo.

“Lynparza conveyed positive results in BRCA-mutated high-risk early breast cancer.“

In addition, the PARP inhibitor decreased the jeopardy of death or distant disease recurrence by forty-three per cent, with fewer deaths occurring in patients receiving Lynparza at the time of the initial data cut-off.

Despite this, the difference in overall survival didn’t attain statistical significance at the time of the interim analysis.

Executive Vice President, Oncology Business Unit, AstraZeneca, Dave Fredrickson, stated: “This is the first time that any medicine targeting a BRCA mutation has demonstrated the potential to change the course of early-stage breast cancer and offer hope for a cure. By providing a treatment which significantly reduces the risk of breast cancer returning in these high-risk patients, we hope Lynparza will set a new benchmark demonstrating sustained clinical benefit. We are working with regulatory authorities to bring Lynparza to these patients as quickly as possible.”

See all the latest jobs in Pharmaceutical
Return to news